Genentech Signs a Development and Commercialization Agreement with Xencor for its IL-15 & XmAb24306 Programs

 Genentech Signs a Development and Commercialization Agreement with Xencor for its IL-15 & XmAb24306 Programs

Genentech Signs a Development and Commercialization Agreement with Xencor for its IL-15 & XmAb24306 Programs

Shots:

  • Xencor to receive $120M upfront, $160M milestones for XmAb24306 program and $180M for IL-15 candidate. Genentech to get worldwide commercialization rights for XmAb24306 & IL-15 program, with Xencor has an option for its co-promotion in the US, sharing equal cost/profit
  • The companies will collaborate for a two-year research program for discovering IL-15 drug candidates, with its expected closure in H1’19
  • XmAb24306 is an IL-15/IL-15Rα cytokine, developed using Xencor’s Fc domain and Xtend Fc technology evaluated in preclinical trials for multiple cancer

Click here read full press release/ article | Ref: PRNewswire | Image: Fatherly

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post